Zeng Rui, Li Yi, He Dong-Ming, Sun Meng-Zhu, Huang Wen-Qing, Wang Yu-Hang, Zhuo Yu-Min, Chen Jun-Jiang, Chen Tai-Heng, Guo Jing-Hui, Huang Jun
Department of Physiology, School of Medicine, Jinan University, Guangzhou, China.
Department of Urology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Front Oncol. 2022 Sep 28;12:1013324. doi: 10.3389/fonc.2022.1013324. eCollection 2022.
Clear cell renal cell carcinoma (ccRCC) accounts for 80% of renal cell carcinomas (RCCs), and its morbidity and prognosis are unfavorable. Surgical resection is the first-line treatment for ccRCC, but the oncogenesis of ccRCC is very complex. With the development of high-throughput sequencing technology, it is necessary to analyze the transcriptome to determine more effective treatment methods. The tumor microenvironment (TME) is composed of tumor cells, various immune-infiltrating cells, fibroblasts, many cytokines, and catalysts. It is a complex system with a dynamic balance that plays an essential role in tumor growth, invasion, and metastasis. Previous studies have confirmed that potassium channels can affect the immune system, especially T lymphocytes that require potassium channel activation. However, the effect of potassium channels on the TME of ccRCC remains to be studied. Therefore, this study aims to construct a prognostic signature for ccRCC patients based on potassium ion channel-related genes (PCRGs), assess patient risk scores, and divide patients into high- and low-risk groups based on the cutoff value. In addition, we investigated whether there were differences in immune cell infiltration, immune activator expression, somatic mutations, and chemotherapeutic responses between the high- and low-risk groups. Our results demonstrate that the PCRG signature can accurately assess patient prognosis and the tumor microenvironment and predict chemotherapeutic responses. In summary, the PCRG signature could serve as an auxiliary tool for the precision treatment of ccRCC.
透明细胞肾细胞癌（ccRCC）占肾细胞癌（RCC）的80%，其发病率和预后不佳。手术切除是ccRCC的一线治疗方法，但ccRCC的肿瘤发生非常复杂。随着高通量测序技术的发展，有必要分析转录组以确定更有效的治疗方法。肿瘤微环境（TME）由肿瘤细胞、各种免疫浸润细胞、成纤维细胞、多种细胞因子和催化剂组成。它是一个具有动态平衡的复杂系统，在肿瘤生长、侵袭和转移中起着至关重要的作用。先前的研究证实，钾通道可以影响免疫系统，尤其是需要钾通道激活的T淋巴细胞。然而，钾通道对ccRCC肿瘤微环境的影响仍有待研究。因此，本研究旨在基于钾离子通道相关基因（PCRG）构建ccRCC患者的预后特征，评估患者风险评分，并根据临界值将患者分为高风险组和低风险组。此外，我们研究了高风险组和低风险组在免疫细胞浸润、免疫激活剂表达、体细胞突变和化疗反应方面是否存在差异。我们的结果表明，PCRG特征可以准确评估患者预后和肿瘤微环境，并预测化疗反应。总之，PCRG特征可作为ccRCC精准治疗的辅助工具。
